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Introduction
Every year about 40 out of 100,000 children under 16 years of age are affected 
by epilepsy as one of the most widespread neurologic disorders worldwide (1). 
Approximately one third of epileptic children do not achieve complete seizure 
improvement in spite of equal or more two antiepileptic therapies, i.e. refractory 
epilepsy (2-3). Election of the most suitable anticonvulsant for an epileptic patient 
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Approximately one third of epileptic children are resistant to anticonvulsant 
drugs. This study evaluates the effectiveness, safety, and tolerability of 
pregabalin as adjunctive therapy in epileptic children relative to Zonisamide.
Materials & Methods
From April 2012 to November 2012,121 children were referred to Mofid 
Children’s Hospital with intractable epilepsy and enrolled in the study. The 
patients were divided into two groups (A and B) randomly. Group A was treated 
with Zonisamide and group B was treated with Pregabalin in addition to prior 
medication. We assessed seizure frequency and severity during a 4-week interval 
from the beginning of the drug treatment and compared the efficacy of each in 
these two groups.
Results
Group A consists of 61 patients, 26 (42.6%) girls, and35 (57.4%) boys with 
an age range from 1.5 months–14 years (mean, 73.9± 44.04 months). Group B 
consists of 60 patients, 31(51.7%) girls, 29 (48.3%) boys with an age range from 
6 months–16 years (mean, 71±42.9 months). Age, gender, seizure onset, seizure 
frequency, seizure type, and previous antiepileptic medications showed that 
there was no significant difference between the groups (P>0.05). Zonisamide 
and pregabalin reduced more than 50% of seizure intensity in 40.2%; 45.8% of 
patients also had a seizure frequency decline between35.8–44.4%, respectively 
and there was no significant superiority between these two novel anticonvulsants 
(P>0.05).
Conclusion
In this survey both pregabalin and Zonisamide were impressive for seizure 
control in children with intractable epilepsy and well sustained with mild 
complications that were completely reversible. 
Keywords: Epileptic children; Intractable Epilepsy; Antiepileptic drugs; 
Zonisamide; Pregabalin
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regarding new AEDs utility in treatment of children 
with refractory epilepsy, the current assay was carried 
out to evaluate the effectiveness, safety, and tolerability 
of pregabalin as an adjunctive therapy relative to that of 
Zonisamide.
Materials & Methods 
From April 2012 to November 2012,121 children were 
referred to Mofid Children’s Hospital with intractable 
epilepsy (failure of seizure recovery in spite of two 
or more antiepileptic drugs) and were enrolled in 
the study. Exclusion criterion was hypersensitivity 
to anticonvulsants and having a neurodegenerative 
disease. All parents endorsed a written informed 
consent. The initial assessment included history 
taking (seizure type, onset, etiology and frequency, 
period of the treatment, type of antiepileptic drug 
usage), general and neurologic physical examination, 
electroencephalography (EEG), and magnetic resonance 
imaging (MRI) performance. Then, the patients were 
divided into two groups randomly (A and B).Group A 
was treated with Zonisamide while patients in group B 
received Pregabalin. We treated group A with capsules 
of ZNS (2–12 milligram per kilogram daily) as group B 
were treated with capsules of PGB (5–15 milligram per 
kilogram daily)divided in two or three doses in addition 
to prior medication. We assessed seizure frequency, 
severity, and duration during the 4 week interval from 
the beginning of treatment and compared the efficacy of 
each drug in the two groups. During follow-ups, seizure 
frequency or severity reduction equal and greater than 
50%istermedas a response to the drug. A paired sample 
T-test, Z-test, and chi-square have been used in the 
statistical analysis. All of the ethical perspectives of this 
study have been confirmed by the Ethics Committee of 
Shahid Beheshti University of Medical Sciences. This 
study was registered in the Iranian Registry of Clinical 
Trial (IRCT) as IRCT2012091210508N4. 
Results
In this study, 137 patients were enrolled and121 patients 
reached the final stage. Table 1 lists the details of 
patient specifications. Group A consists of 61 patients, 
26 (42.6%) girls, 35 (57.4%) boys with an age range 
of1.5 months–14 years (mean, 73.9± 44.04 months) 
is problematic as the performance of the approved first-
line treatments does not significantly differ. The primary 
evaluation proceeding for a new antiepileptic drug 
implicates its efficacy confirmation as an add-on therapy 
for a decline in seizure frequency in patients who have 
intractable seizures (4-5). Zonisamide (1,2 benzisoxazole-
3-methane sulfonamide) is a new production antiepileptic 
drug authorized as monotherapy and adjunctive therapy 
of intractable partial epilepsies. Zonisamide (ZNS) 
is effective in children with generalized epilepsies, 
notably for myoclonic seizures. Chemical organization 
(non-arylamine sulfonamide) and various manners of 
antiepileptic activity make ZNS incomparable to other 
antiepileptic drugs(AEDs). The main biochemical 
effect of ZNS is voltage linked sodium and T-type 
calcium channel blocking; however, glutamate related 
synaptic stimulation decline, gamma-aminobutyric 
acid (GABA) release from the hippocampus, neuronal 
hyper synchronization suppression, hydroxyl and oxide 
radicals elimination, and erythrocyte carbonic anhydrase 
deterrence are the other mechanisms. ZNS is absorbed 
rapidly and reaches peak plasma concentrations in 
2–6 h after oral consumption. Additionally, it has high 
(95%) bioavailability (6-11). Pregabalin (PGB) has 
the structural equivalent of GABA but has no effects 
associated with GABA or GABA receptors(12).PGB is 
a selective high-propensity ligand for the α2-δ subunit 
of presynaptic voltage gated calcium channels. Intense 
binding to this channel diminishes calcium entrance 
at hyper excitable nerve terminations to lower the 
distribution of several neurotransmitters consisting of 
glutamate, norepinephrine, and substance P.A reduction 
of these neurotransmitters and neuronal excitability 
that this drug acts on leads to it as an anticonvulsant, 
analgesic, and anxiolytic efficacy(13-16).It has a linear 
dose–concentration curve that is among the most 
effectual dose span (150–600 mg/day) and extensively 
absorbed after oral dosing with 90% bio availability 
that after1 h reaches peak plasma concentrations. PGB 
is much more vigorous (2 to 18 fold) than gabapentin 
between all seizure types tested (17).Efficacy of PGB 
as an add-on therapy for patients with refractory partial 
epilepsies was evaluated through several controlled 
trials (18-19).
As there is an insignificant amount of information 
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group A toward 15(25%),32(53.33%), and 13 (21.66%) 
patients of group B had no change, greater than 50% 
recovery, and reduction less than 50%, respectively 
(Figure1). Also,25(41%),19 (31.1%),14(23.9%), and 
3(4.9%) patients of group A compared to 18(30%),23 
(38.33%),17(28.3%), and 2(3.3%) patients of group 
B were not changed, reduced greater than 50%, had 
reduction lower than 50%, and had worsened in the 6 
months follow-up, respectively(Figure1).There was no 
significant difference between these two groups in view of 
seizure frequency, duration, and severity reduction after 
one(P=0.591) and six (P=0.607) months reviews. First 
month reviews showed that infantile spasms (85.7%), 
generalized tonic clonic (58.8%), and myoclonic 
(54.5%) seizures compared to partial (70.2%), tonic 
(60%), and generalized tonic clonic (40.9%) were the 
types of seizures with the highest response to ZNS and 
PGB respectively. The highest response to ZNS and PGB 
were in seizure types as follows: Myoclonic (54.5%), 
infantile spasms (47.1%), and generalized tonic clonic 
(42.9%) versus partial (53.2%), tonic (50%), and atonic 
(40%) during six-month review, respectively. There 
was no seizure response to mixed type and myoclonic 
seizures by ZNS and PGB, respectively, within the first 
or six months assay.
Discussion
This study showed that ZNS and PGB reduced greater 
than 50% of the seizure intensity in 40.2% and 45.8% of 
patients also had seizure frequency declinesof35.8% and 
44.4%, respectively in which there was no significant 
superiority between these two novel anticonvulsants. 
Brodie et al, Sackellares et al, Faught et al, and Schmidt 
et al reported a response rate (greater than 50% seizure 
reduction) of 28–47% with ZNS as an add-on therapy 
for intractable epilepsy through four clinical studies (20). 
ZNS effectiveness in the current assay is in agreement 
with Coppola et al and Stephen who declared a frequency 
decline of greater than 50% between 48.7–39% of 
patients, respectively(21-22).No preference between 
these two drugs that we found is different from Claudia 
B et al and Yuen et al who estimated that with a ZNS 
retention rate of 31% compared to 24% for PGB after 
six months period (23-24).In our review, the efficacy 
of both drugs has been diminished after six months of 
(Table.1). Group B consists of 60 patients, 31(51.7%) 
girls, 29 (48.3%)boys with an age range from 6 months 
to 16 years (mean, 71±42.9 months) (Table.1).The 
mean age of seizure onset in group A and group B 
was 27.1±28.1 and 23.15±24.3 months, respectively. 
The mean seizure frequency per day in group A was 
5.43±7.21 with attacks ranging from 3 every month to 
50 daily. The mean seizure frequency per day in group B 
was 4.65±3.77 with attacks ranging from 3 every month 
to 20 daily. The most common seizure form in group 
A was generalized tonic clonic, partial, and myoclonic 
seizures in 17 (27.9%),16(26.3%),and 11(18%)children, 
respectively (Table1).The most common seizure form in 
22 (36.7%),16(26.3%),and 8(13.3%)children of group 
B was generalized tonic clonic, partial, and mixed type 
seizures, respectively (Table1).According to seizure 
etiology 26(42.62%),24 (39.34%), and 11 (18%) patients 
of group A were classified as idiopathic, cryptogenic, and 
symptomatic epilepsy, respectively (Table1).Idiopathic, 
cryptogenic, and symptomatic epilepsy were seizure 
etiology of 23(38.3%),30 (49.18%), and 7 (11.7%) 
patients of group B, respectively (Table1).The EEG 
findings were normal, mild, moderate, and severely 
abnormal in 4 (6.57%), 18 (29.5%), 24 (39.34%), and 15 
(24.6%)children of group A, respectively(Table 1).The 
EEG findings in 4 (6.57%), 17 (28.3%), 25 (41.66%), 
and 14 (23.33%)children of group B were normal, mild, 
moderate, and severely abnormal, respectively(Table 
1). Patients of group A had used a minimum 3 and 
maximum of 15 anti-seizure medications, the average 
number of 7.11±2.97 prior to this study. Patients of group 
B had used minimum 3 and maximum of 13 anti-seizure 
medications, the average number of 7.28±2.92 prior to 
this study. Age, gender, seizure onset, seizure frequency, 
seizure type, and previous antiepileptic medications 
indicated there were no significant differences between 
these two groups (P>0.05).
After one and six months of ZNS usage, daily seizure 
frequency decreased to 2.95±3.54as 45.7% reduction 
and 3.73±3.5 as 31.3% reduction, respectively. PGB 
after one and six months reduced seizure frequency up to 
2.41±2.38as a 48% reduction and 2.75±2.38 as a 40.86% 
reduction respectively. According to improvements 
in seizure severity and duration after one month, 
17(27.9%),30(49.2%), and 14 (22.9%) patients of 
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occurred with ZNS and PGB dose greater than or equal 
to 200vs 150 mg/day in patients over 6vs 7 years of 
age, respectively. The incidence of ZNS complications 
in the current assay is insignificant compared to Tan et 
al (43.9%), Stephen (28.6%) and Claudia et al(58%) 
detections. Since, usually PGB has been used in the 
treatment of adults with epilepsy that requires at least 
300 mg/day. Its complications incidence in n Lee et al 
(64.7%), Terence et al (50%), and Elger et al (32.8%) 
surveys were greater than our results. Weight gain was 
the most common side effect of PGB in our patients 
and was also Pradeep, Arroyo et al, and Terence et al 
reported 5–7% weight enhancement among 24–50% of 
those who took it.
In conclusion, in this survey both pregabalin and 
Zonisamide were impressive for seizure control in 
children with intractable epilepsy and well sustained 
with mild complications that were completely reversible. 
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treatment towards one month of consumption.  Loscher 
et al has observed that the efficacy of antiepileptic drugs 
decreased over time due to drug receptor sensitivity 
decreases that led to pharmaco dynamic tolerance that 
can further lead to loss of drug function completely or 
could interfere with other anticonvulsant activity via 
cross tolerance(25).Similar to our results, Arroyo et al 
stated that 43.5% of patients with refractory epilepsy 
responded to PGB therapy. Furthermore, this study found 
a dose-dependent response to this drug at the higher dose 
equal to 600 mg per day was quite effective(15).Terence 
et al examined the effects of lamotrigine compared with 
pregabalin on refractory partial seizures in a 17-week 
treatment period and concluded that PGB reduced greater 
than 50% of seizure intensity in 35.5% of cases toward 
the lamotrigine efficacy in 21.4% of patients(26).Lee et 
al observed seizure declines in 46.2% of patients after 
13 weeks of PGB treatment, which confirmed our result 
(27). Elger et al detected PGB antiepileptic efficacy more 
than our results who treated patients with a constant dose 
of PGB (600mg/day) and later 12 weeks found 49.3% 
seizure improvement (19).This discrepancy may be due 
to a wide spectrum of PGB dosage (5-15mg/kg/day), 
which takes a few weeks to achieve a fixed amount 
of the drug’s availability in patients. Pradeep found a 
significant PGB induced reduction in the frequency and 
severity of seizures of up to 56% among patients with 
various seizure types and those who had previously not 
responded to gabapentin had no response to PGB(28).
Our study showed that three patients who had used 
gabapentin previously did not respond to PGB against 
Pradeep’s results. The highest response to ZNS in our 
case was obtained in seizure types of infantile spasms 
(66.4%), myoclonic (54.5%), and generalized tonic 
clonic (50.9%) with no effect on mixed type seizures. 
Partial seizures (61.7%), tonic (55%), and generalized 
tonic clonic (40.9%) were the seizure kinds with the 
highest response to PGB in our patients with no effect 
on myoclonic seizure. PGB and ZNS had complication 
rate of 18.33–16.4%, respectively. Decreased appetite, 
impaired speech, ataxia, sigh, visual disturbances, 
hallucinations, and dizziness versus increased appetite, 
increased urination, hallucinations, and headache 
have been the most prevalent side effects of ZNS and 
PGB, respectively. All of our patients’ complications 
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Fig 1. Seizure reduction in the first month follow-up 
Fig 2. Seizure reduction in the six-month follow-up 
55Iran J Child Neurol. 2015 Winter Vol 9 No 1
33.
9. Baulac, M. Introduction to zonisamide. Epilepsy Res 
2006; 68(Suppl. 2):S3-S9.
10. Heo K, Lee BI, Yi SD, Cho YW, Shin DJ, Song HK, 
Kim OJ, Park SP, Kim SE, Kim SH, Lee JH, Kim KS, 
Lee SJ. Short-term efficacy and safety of zonisamide as 
adjunctive treatment for refractory partial seizures: A 
multicenter open-label single-arm trial in Korean patients. 
Seizure 2012; 21:188-193.
11. Hwang H, Kim KJ. New antiepileptic drugs in pediatric 
epilepsy. Brain Dev 2008; 30(9):549-55.
12. Fehrenbacher JC, Taylor CP, Vasko MR.Pregabalin and 
gabapentin reduce release of substance P and CGRP from 
rat spinal tissues only after inflammation or activation of 
protein kinase C. Pain 2003; 105:133–141.
13. Field MJ, Cox PJ, Stott E, Melrose H, Offord J, Su T-Z, 
Bramwell S, Corradini L, England S, Winks J, Kinloch 
RA, Hendrich J, Dolphin AC, Webb T, Williams D. 
Identification of the α2-δ-1 subunit of voltage-dependent 
calcium channels as a molecular target for pain mediating 
the analgesic actions of pregabalin. PNAS 2006; 103: 
17537–17542.
14. Taylor CP, Angelotti T, E. Pharmacology and mechanism 
of action of pregabalin: The calcium channel α2-δ (alpha2-
delta) subunit as a target for antiepileptic drug discovery. 
Epilepsy Res 2007; 73: 137–150.
15. Ben-Menachem E. Pregabalin pharmacology and its 
relevance to clinical practice. Epilepsia 2004; 45(Suppl. 
6):13–18.
16. Taylor CP, Angelotti T, E. Pharmacology and mechanism 
of action of pregabalin: the calcium channel alpha2delta 
(alpha2-delta) subunit as a target for antiepileptic drug 
discovery.Epilepsy Res 2007; 73:137—150.
17. French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo 
EA. Dose-response trial of pregabalin adjunctive therapy 
in patients with partial seizures. Neurology 2003; 
60:1631–1637.
18. Elger CE, Brodie MJ, Anhut H, Lee CM, Barrett JA. 
Pregabalin add-on treatment in patients with partial 
seizures: a novel evaluation of flexible-dose and fixed-
dose treatment in a double-blind, placebo controlled 
study. Epilepsia 2005; 46:1926–1936.
19. Arroyo S, Anhut H, Kugler AR, Lee CM, Knapp 
Comparative Efficacy of Zonisamide and Pregabalin as an Adjunctive Therapy in Children with Refractory Epilepsy
LE, Garofalo EA, S. Pregabalin add-on treatment: a 
randomized, double-blind, placebo-controlled, dose-
response study in adults with partial seizures. Epilepsia 
2004; 45: 20-27.
20. Baulac M, IE. Efficacy and safety of adjunctive zonisamide 
therapy for refractory partial seizures.Epilepsy Research 
2007; 75: 75-83.
21. Stephen LJ, Kelly K, Wilson EA, Parker P, Brodie MJ.A 
prospective audit of adjunctive zonisamide in an everyday 
clinical setting. Epilepsy Behav 2010; 17(4):455-60. 
22. Baulac M, Leon T, O’Brien TJ, Whalen E, Barrett J.A 
comparison of pregabalin, lamotrigine, and placebo as 
adjunctive therapy in patients with refractory partial-onset 
seizures. Epilepsy Research 2010; 91:10-19.
23. Lee BI, Yi S, Hong SB, Kim MK, Lee SA, Lee SK, 
Shin DJ, Kim JM, Song HK, Heo K, Lowe W, Leon T. 
Pregabalin add-on therapy using a flexible, optimized 
dose schedule in refractory partial epilepsies: A double 
blind, randomized, placebo-controlled, multicenter trial. 
Epilepsia 2009; 50(3):464–474.
24. Modur PN, Milteer WE. Adjunctive pregabalin therapy in 
mentally retarded, developmentally delayed patients with 
epilepsy. Epilepsy & Behavior 2008; 13: 554–556.
25. Coppola G, Grosso S, Verrotti A, Parisi P, Luchetti A, 
Franzoni E, Mangano S, Pelliccia A, Operto FF, Iannetti 
P, Curatolo P, Balestri P, A. Zonisamide in children and 
young adults with refractory epilepsy: An open label, 
multicenter Italian study. Epilepsy Research 2009; 83: 
112-116.
26. Tan HJ, Martland TR, Appleton RE, R. Effectiveness and 
tolerability of zonisamide in children with epilepsy: A 
retrospective review. Seizure 2010; 19:31–35.
27. Catarino CB, Bartolini E, Bell GS, Yuen AW, Duncan JS, 
Sander JW. The long-term retention of zonisamide in a 
large cohort of people with epilepsy at a tertiary referral 
centre.Epilepsy Research 2011; 96:39-44.
28. Loscher W, Schmidt D. Experimental and clinical 
evidence for loss of effect (tolerance) during prolonged 
treatment with antiepileptic drugs. Epilepsia 2006; 
47(8):1253-84.
